Skip to content
Disclosery

Cutter Capital Management, LP

Follow

13F filer, CIK 1983313, NEW YORK, NY

Cutter Capital Management, LP reported $244,038,058 across 21 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-14. Its ten largest share positions make up 68.7% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001214659-25-002829

Period
2024-12-31
Reported value
$244M
Holdings
21
Top 10 weight
68.7%
New
11
Sold out
17

Largest buys vs the previous quarter

SecurityShares changeApprox. value
JNJnew+141,572$20.5M
ABBVnew+101,996$18.1M
TEVAnew+584,883$12.9M
REGNadded+17,024$12.1M
AMGNnew+38,090$9.93M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
GILDexited-359,025-$30.1M
BMYexited-574,057-$29.7M
Aexited-120,485-$17.9M
LEGNexited-325,953-$15.9M
LLYexited-17,299-$15.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0001214659-25-002829, largest first. % of portfolio is the value over $244,038,058, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
REGNREGENERON PHARMACEUTICALSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 16,360 shares; 2024Q2: not reported; 2024Q3: 14,476 shares; 2024Q4: 31,500 shares 31,500$22.4M9.19%+17,024Timeline
JNJJOHNSON & JOHNSONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 141,572 shares 141,572$20.5M8.39%newTimeline
RPRXROYALTY PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 370,000 shares; 2024Q1: 411,540 shares; 2024Q2: 692,300 shares; 2024Q3: 664,859 shares; 2024Q4: 764,859 shares 764,859$19.5M8%+100,000Timeline
ABBVABBVIE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 101,996 shares 101,996$18.1M7.43%newTimeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 365,000 shares; 2024Q3: 286,803 shares; 2024Q4: 406,803 shares 406,803$17.1M7.01%+120,000Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 103,324 shares; 2024Q1: not reported; 2024Q2: 311,700 shares; 2024Q3: 396,388 shares; 2024Q4: 560,344 shares 560,344$15.4M6.3%+163,956Timeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 94,379 shares; 2024Q2: 89,379 shares; 2024Q3: 83,756 shares; 2024Q4: 124,256 shares 124,256$15.1M6.19%+40,500Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 413,499 shares; 2024Q1: 227,337 shares; 2024Q2: 227,637 shares; 2024Q3: 215,884 shares; 2024Q4: 210,884 shares 210,884$14.6M5.97%-5,000Timeline
TEVATEVA PHARMACEUTICAL INDS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 1,061,668 shares; 2024Q1: 1,135,710 shares; 2024Q2: 911,900 shares; 2024Q3: not reported; 2024Q4: 584,883 shares 584,883$12.9M5.28%newTimeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 307,721 shares; 2024Q1: 278,638 shares; 2024Q2: not reported; 2024Q3: 518,677 shares; 2024Q4: 628,677 shares 628,677$12.1M4.94%+110,000Timeline
AMGNAMGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 57,381 shares; 2024Q1: not reported; 2024Q2: 64,201 shares; 2024Q3: not reported; 2024Q4: 38,090 shares 38,090$9.93M4.07%newTimeline
AGIOAGIOS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 288,580 shares; 2024Q2: not reported; 2024Q3: 186,623 shares; 2024Q4: 301,623 shares 301,623$9.91M4.06%+115,000Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 230,000 shares; 2024Q3: 172,876 shares; 2024Q4: 212,696 shares 212,696$8.99M3.69%+39,820Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 337,152 shares 337,152$8.66M3.55%newTimeline
MRNAMODERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 197,500 shares 197,500$8.21M3.37%newTimeline
PRGOPERRIGO CO PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 260,000 shares; 2024Q1: 322,114 shares; 2024Q2: 100,000 shares; 2024Q3: 557,937 shares; 2024Q4: 294,517 shares 294,517$7.57M3.1%-263,420Timeline
JANXJANUX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 120,000 shares 120,000$6.42M2.63%newTimeline
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 230,000 shares 230,000$6.4M2.62%newTimeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 112,500 shares 112,500$6.23M2.55%newTimeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 147,076 shares 147,076$2.46M1.01%newTimeline
NMRANEUMORA THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 150,000 shares 150,000$1.59M0.65%newTimeline

Sold out in Q4 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
GILDGILEAD SCIENCES INC359,025$30.1Mshares
BMYBRISTOL-MYERS SQUIBB CO574,057$29.7Mshares
AAGILENT TECHNOLOGIES INC120,485$17.9Mshares
LEGNLEGEND BIOTECH CORP325,953$15.9Mshares
LLYELI LILLY & CO17,299$15.3Mshares
HRMYHARMONY BIOSCIENCES HLDGS IN376,315$15.1Mshares
JAZZJAZZ PHARMACEUTICALS PLC117,500$13.1Mshares
SPRINGWORKS THERAPEUTICS INCSPRINGWORKS THERAPEUTICS INC378,453$12.1Mshares
AXSMAXSOME THERAPEUTICS INC.105,767$9.51Mshares
IOVAIOVANCE BIOTHERAPEUTICS INC876,009$8.23Mshares
NTLAINTELLIA THERAPEUTICS INC390,622$8.03Mshares
ACLXARCELLX INC89,863$7.5Mshares
RNAMAVIDITY BIOSCIENCES INC160,947$7.39Mshares
BCRXBIOCRYST PHARMACEUTICALS INC798,137$6.07Mshares
ELVNENLIVEN THERAPEUTICS INC207,896$5.31Mshares
AVADEL PHARMACEUTICALSAVADEL PHARMACEUTICALS385,172$5.05Mshares
IONSIONIS PHARMACEUTICALS INC97,300$3.9Mshares

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001214659-25-002829 base2025-02-14acceptance time not in the bulk data set